At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDX Celldex Therapeutics
Trading 02-05 12:46:49 EST
23.37
-0.90
-3.71%
High24.34Low23.27Vol412.81K
Open24.04D1 Closing24.27Amplitude4.41%
Mkt Cap1.55BTradable Cap1.24BTotal Shares66.45M
T/O9.83MT/O Rate0.78%Tradable Shares53.21M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses
Simply Wall St.  ·  02-04 13:24
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
TIPRANKS  ·  01-22
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
Celldex (CLDX) Gets a Buy from Mizuho Securities
TIPRANKS  ·  01-09
Celldex (CLDX) Gets a Buy from Mizuho Securities
Barclays Remains a Sell on Celldex (CLDX)
TIPRANKS  ·  01-09
Barclays Remains a Sell on Celldex (CLDX)
Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy
Reuters  ·  01-08
Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy
Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?
Simply Wall St.  ·  2025-12-22
Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?
Celldex Therapeutics Is Maintained at Underweight by Barclays
Dow Jones  ·  2025-12-18
Celldex Therapeutics Is Maintained at Underweight by Barclays
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?
Simply Wall St.  ·  2025-12-11
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?
BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
Reuters  ·  2025-12-09
BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
Celldex Therapeutics Inc - Data From Open Label Extension Expected in Q1 2026
THOMSON REUTERS  ·  2025-12-09
Celldex Therapeutics Inc - Data From Open Label Extension Expected in Q1 2026
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
THOMSON REUTERS  ·  2025-12-09
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares
Reuters  ·  2025-12-09
Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares
How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses
Simply Wall St.  ·  2025-11-22
How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses
Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings
Simply Wall St.  ·  2025-11-19
Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings
Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
Reuters  ·  2025-11-19
Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver
Reuters  ·  2025-11-13
Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver
Celldex Therapeutics Is Maintained at Underweight by Barclays
Dow Jones  ·  2025-11-11
Celldex Therapeutics Is Maintained at Underweight by Barclays
Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)
TIPRANKS  ·  2025-11-11
Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)
Mizuho Securities Remains a Buy on Celldex (CLDX)
TIPRANKS  ·  2025-11-11
Mizuho Securities Remains a Buy on Celldex (CLDX)
Barclays Sticks to Its Sell Rating for Celldex (CLDX)
TIPRANKS  ·  2025-11-11
Barclays Sticks to Its Sell Rating for Celldex (CLDX)

Introduction

Company Name.
Celldex Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Issue price:
--